Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus standard-dose adjuvant chemotherapy for high-risk node-positive breast cancer
ACTRN12607000025437Phase 3Completed
- Sponsor
- International Breast Cancer Study Group
- Start
- Oct 1995
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cyclophosphamide, doxorubicin, methotrexate, fluorouracil and 3 more in breast cancer (2 arms), sponsored by International Breast Cancer Study Group. Primary endpoints: Overall survival and Duration quality-adjusted time without symptoms and toxicity (TWiST and Q-TWiST). Started Oct 1995; status: completed.
02
Drugs
epirubicincyclophosphamidedoxorubicinmethotrexatefluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12607000025437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000025437.